Key facts
- Operator of a biotech company intended to develop a pipeline of small molecules by studying their effects on brain cells derived from induced pluripotent stem cells.
- It has raised $4.0M; the latest was Accelerator/Incubator in Oct 2025.
- Notable investors include LvlUp Ventures, Endless Frontier Labs, Harvard Alumni Entrepreneurs, Mark Pavao, SynGAP Research Fund.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for 4M Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for 4M Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About 4M Therapeutics
Operator of a biotech company intended to develop a pipeline of small molecules by studying their effects on brain cells derived from induced pluripotent stem cells. The platform is based on identifying and optimizing novel small molecules based on how they affect living human brain cells in the laboratory, with a focus on regenerative pathways in the brain, enabling clients to improve the lives of patients suffering from neuropsychiatric disorders and neurodegenerative diseases.
- Sector
- Healthcare
- HQ
- Skillman, NJ, United States
- Founded
- 2021
- Employees
- 5
- Website
- 4mtx.net/
- Ownership
- Privately Held (backing)
4M Therapeutics doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.